Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Targeted Protein Degradation | Industry Spotlights & Insight Articles

Targeting Novel E3 Ubiquitin Ligases: Carles Galdeano, Professor, University of Barcelona

Edited by Tom Cohen | 01 December 2023
We discuss working on PROTACs, targeting novel E3 ubiquitin ligases, and Dr Galdeano's spin out Oniria Therapeutics.

 

Like this interview? See more below:

 

Join and network with over 450 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation
and HIT optimisation of small and large molecule drugs.

Speaker Biographies

Dr Carles Galdeano is currently a Serra Hunter Lecturer Professor at University of Barcelona. He obtained his PhD in medicinal chemistry at University of Barcelona with two visiting stays at Virginia Tech (USA) and CNRS (France). After that, he spent three years post-doc in the Alessio Ciulli’s lab (first at University of Cambridge and later at University of Dundee) where together they develop the first potent VHL ligands described. His postdoctoral discoveries represented a breakthrough in the PROTACS field. In 2015, he returned to the University of Barcelona to work in collaboration with Prof Barril with a Beatriu de Pinos Fellowship until 2019, when he started his independent research group.

Related Events

For more on this topic, you may be interested in our upcoming Discovery Europe 2024

Related Resources

From Screening to Success: How Molecular 'Super-Glue' SJ3149, Could Advance Cancer Treatments

Researchers at St Jude Children's Research Hospital used high throughput screening (HTS) to identify SJ3149, a molecular glue degrader. This small molecule demonstrated efficacy across a range of cancer types.
Read More

Talking TPD with Ben Cross, CTO and Head of Platform at PhoreMost

Delving into PhoreMost's role in targeted protein degradation, the innovation behind the SITESEEKER platform, and the challenges and breakthroughs in the dynamic field of drug discovery.
Read More